How I treat refractory and relapsed acute myeloid leukemia
Using a series of 3 illustrative cases, Thol and colleagues discuss their approach to relapsed/refractory acute myeloid leukemia. Although allogeneic hemat
Related Articles
David versus Goliath
Nature – Resources are shifting from small labs led by one researcher to large teams with expensive equipment. But has the rise of big biology…
Biology of post-transplant relapse: actionable features
Abstract. In patients receiving allogeneic hematopoietic cell transplantation to cure acute myeloid leukemia (AML), recurrence of the underlying disease, o
Maintenance strategies for relapse prevention and treatment
Abstract. Posttransplant relapse is the most significant challenge in allogeneic stem cell transplantation (alloSCT). Posttransplant interventions, in conj
Project Facilitate: 5 Years of Progress, Outreach, and Service
OCE Insights is developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the FDA. In this installment, the authors…
Association between COVID-19 infection and new-onset dementia in older adults: a systematic review and meta-analysis – BMC Geriatrics
Background The relationship between COVID-19 infection and a possible increased likelihood of older adults developing new-onset dementia (NOD) remains elusive. Methods A thorough search was…
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Nature – A study reporting the results of a clinical trial co-administering the GDF-15-blocking antibody visugromab with the anti-PD-1 antibody nivolumab demonstrates that neutralizing GDF-15…
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to pro
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms
In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic…
Daniel Siegwart, Ph.D., named fellow of the National Academy of Inventors
Daniel Siegwart, Ph.D., Professor in the Departments of Biomedical Engineering and Biochemistry and in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical…